Sun Pharmaceutical Industries Ltd, India’s largest pharmaceutical company, is evaluating a major overseas acquisition, according to media reports. The company is reportedly in discussions to acquire US-based Organon, a global pharmaceutical firm with a strong focus on women’s health and an expanding portfolio in the biosimilars segment.
The proposed deal is estimated to be valued at around $10 billion, including debt, and would rank as the largest cross-border acquisition in the Indian pharmaceutical industry to date. A successful transaction would significantly enhance Sun Pharma’s scale and presence in the US market, while also strengthening its position in high-growth therapeutic areas such as women’s healthcare and complex biologics.
While discussions are understood to be at an exploratory stage, the acquisition aligns with Sun Pharma’s strategy to deepen its global footprint and diversify its product portfolio through strategic inorganic growth.